Aptose Biosciences Inc. Given Consensus Recommendation of Buy by Analysts
LSTA Stock | USD 2.53 0.05 1.94% |
About 62% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lisata |
Shares of Aptose Biosciences Inc. have been assigned an average rating of Buy from the six research firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued ratings on
Read at thelincolnianonline.com
Lisata Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lisata Therapeutics Fundamental Analysis
We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Lisata Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Lisata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.
Peers
Lisata Therapeutics Related Equities
BPTH | Bio Path | 158.21 | ||||
CADL | Candel Therapeutics | 54.67 | ||||
PTIX | Protagenic Therapeutics | 14.29 | ||||
IMNN | Imunon | 3.57 | ||||
RZLT | Rezolute | 2.70 | ||||
PULM | Pulmatrix | 2.15 | ||||
TPST | Tempest Therapeutics | 0.80 | ||||
XOMAO | XOMA | 0.08 | ||||
MBRX | Moleculin Biotech | 2.13 | ||||
ANTX | AN2 Therapeutics | 4.48 | ||||
LIXT | Lixte Biotechnology | 5.24 | ||||
GLUE | Monte Rosa | 14.47 |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Money Managers Screen money managers from public funds and ETFs managed around the world |